state of coverage and reimbursement of genetic tests and services, highlights concerns that affect patient access to tests and services, and identifies nine steps that HHS and the private sector could take to help improve access to and appropriate utilization of health-related genetic tests and services.

2. *Large population studies.* In March 2007, SACGHS issued a report, *Policy Issues Associated with Undertaking a Large U.S. Population Cohort Project on Genes, Environment, and Disease.* The report delineates the questions that need to be addressed for policymakers to determine whether the U.S. Government should undertake a large population project to elucidate the influence of genetic variation and environmental factors on common, complex diseases.

3. *Genetic discrimination.* SACGHS has written three letters to the HHS Secretary championing the enactment of Federal legislation to prohibit discrimination based on genetic information by health insurers and employers. The Committee also provided the Secretary with a legal analysis of the adequacy of current law regarding genetic discrimination, a compendium of public comments documenting public fears and concerns about genetic discrimination, and a 10-minute DVD of testimonies received from the public.

4. *Genetics education and training of health professionals.* SACGHS issued a resolution that urged the HHS Secretary to take a series of steps to ensure the adequacy of genetics education and training of health care and public health professionals. Because of continuing needs in this area, SACGHS created a Genetics Education and Training Task Force in November 2007 to develop a plan to identify the education and training needs of health professionals, lay health educators, and the general public; outline the steps required to meet these needs; and evaluate the effectiveness of existing educational and training efforts.

5. *Direct-to-consumer marketing of genetic technologies.* SACGHS wrote two letters to the HHS Secretary urging greater collaboration among Federal agencies in addressing the advertising of laboratory-developed genetic tests. These efforts led to the issuance of a Federal Trade Commission Consumer Alert that cautions consumers that at-home genetic tests have not been evaluated by FDA and urges them to be wary of the claims made by companies marketing such tests.

6. *Oversight of genetic technologies.* In March 2007, the Office of the HHS Secretary charged SACGHS with identifying the steps needed for evidence development and oversight of genetic and genomic tests. A final report on the issue is expected in May 2008.

7. *Pharmacogenomics.* In May 2008, SACGHS will issue its final report on the opportunities and challenges associated with pharmacogenomics research, development of pharmacogenomic applications, and integration of these applications into clinical practice and public health.

8. *Patents and access.* SACGHS is currently studying the positive and negative effects of gene patent and licensing practices on patient access to genetic tests and the public's health. A final report is expected in 2009.

9. *Access to genetic technologies.* This was designated as an overarching issue that cuts across all SACGHS work.

10. *Public awareness and understanding of genetic technologies.* This was designated as an overarching issue that cuts across all SACGHS work.

11. *Genetic exceptionalism.* This was designated as an overarching issue that cuts across all SACGHS work.

SACGHS's work products can be found at: *http://www4.od.nih.gov/oba/sacghs/reports/reports.html.*

As described above, SACGHS has completed several major projects related to these 11 issues, and other projects are near completion. In the coming months, the Committee will be identifying new priority issues to address. SACGHS would welcome public perspectives about issues within SACGHS's charter that are in need of attention and study. Members of the public who wish to suggest an issue are asked to submit a statement (approximately one paragraph in length) that:

(1) Describes a problem or policy challenge that needs exploration; and (2) proposes actions the Committee could take to address the issue. The submission of references or other background materials related to the topic is encouraged.

The issues suggested should take into consideration the charge of SACGHS, outlined above, and the following points:

- The urgency and national importance of the issue.
- The extent to which the Federal Government has jurisdiction/authority over the issue.
- The need for Federal guidance or regulation on this issue.
- Whether the issue raises concerns that only the Federal Government can address.
- Whether the issue raises moral or ethical concerns that warrant Federal Government involvement/leadership.
- Whether SACGHS's policy advice on this issue would significantly benefit society.
- Whether failure to address the issue would prolong any negative impact the issue may be having on society.
- Whether sufficient data about the issue exist for SACGHS to develop informed policy advice.
- Whether another body is already addressing the issue or is better equipped to address it.

Public comments received by May 16, 2008 will be considered by SACGHS and discussed at its next meeting on July 7–8, 2008 in Washington, DC.

Dated: April 7, 2008.

Sarah Carr,

SACGHS Executive Secretary, National Institutes of Health.

[FR Doc. E8–8216 Filed 4–16–08; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Board of Scientific Counselors, Coordinating Center for Infectious Diseases (BSC, CCID)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC), announces the following meeting for the aforementioned committee:

Times and Dates:

9 a.m.–5 p.m., May 6, 2008.

8:30 a.m.–3:30 p.m., May 7, 2008.

Place: CDC Global Conference Center, Building 19, 1600 Clifton Road, NE., Atlanta, Georgia 30333.

Status: Open to the public, limited only by the space available.

Purpose: The Board of Scientific Counselors, CCID, provides advice and guidance to the Director, CDC, and Director, CCID, in the following areas: program goals and objectives; strategies; program organization and resources for infectious disease prevention and control; and program priorities.

Matters to be Discussed: Agenda items will include:

1. *Breakout Group Discussions:*

Surveillance (National Center for Preparedness, Detection, and Control of Infectious Diseases).

Respiratory Diseases Strategic Planning (National Center Immunization and Respiratory Diseases).

Vaccine Analytic Unit (National Center Immunization and Respiratory Diseases).

Program Collaboration and Service Integration (National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention).

International Activities (National Center for Zoonotic, Vector-Borne, and Enteric Diseases).
Strategic Planning and Linking to CDC Goals (National Center for Zoonotic, Vector-Borne, and Enteric Diseases).

2. *Updates on Surveillance Systems:* Biosurveillance.
3. Strategic Directions for CCID.
4. Budget Updates.

Written comments are welcome and should be received by the contact person listed below prior to the opening of the meeting.

Contact Person for More Information: Harriette Lynch, Office of the Director, CCID, CDC, Mailstop A–45, 1600 Clifton Road, NE., Atlanta, Georgia 30333, Telephone (404) 639–4035.

The Director, Management Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: April 9, 2008.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E8–8336 Filed 4–16–08; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Type-2 Diabetes Prevention in Women With a Recent History of Gestational Diabetes Mellitus, Potential Extramural Project (PEP) 2008–R–04.

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting.

Time and Date: 1 p.m.–4 p.m., May 30, 2008 (Closed).

Place: Teleconference.

Status: The meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of ''Type-2 Diabetes Prevention in Women With a Recent History of Gestational Diabetes Mellitus, PEP 2008–R–04.''

Contact Person for More Information: Linda Shelton, Program Specialist, Coordinating Center for Health and Information Service, Office of the Director, CDC, 1600 Clifton Road, NE., Mailstop E21, Atlanta, GA 30333, Telephone (404) 498–1194.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: April 9, 2008.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E8–8326 Filed 4–16–08; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket Number 128]

Notice of Draft Document Available for Public Comment

AGENCY: National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of Draft Document Available for Public Comment.

SUMMARY: The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) announces the availability of the following draft document available for public comment entitled ''Preventing Occupational Exposures to Lead and Noise at Indoor Firing Ranges.'' The draft document and instructions for submitting comments can be found at *http://www.cdc.gov/niosh/review/public/-128/*. Comments should be provided to the NIOSH Docket Number above.

Public Comment Period: April 17, 2008 through June 30, 2008.

Status: Written comments may be submitted to the NIOSH Docket Office, Robert A. Taft Laboratories, 4676 Columbia Parkway, Mailstop C–34, Cincinnati, Ohio 45226. All material submitted to the Agency should reference NIOSH Docket number 128 and must be submitted by June 30, 2008, to be considered by the Agency. All electronic comments should be formatted as Microsoft Word.

All information received in response to this notice will be available for public examination and copying at the NIOSH Docket Office, Room 111, 4676 Columbia Parkway, Cincinnati, Ohio 45226. After the comment period has closed, comments may be accessed electronically at *http://www.cdc.gov/NIOSH* under the link to the NIOSH docket. As appropriate, NIOSH will post comments with the commenters' names, affiliations, and other information, on the Internet.

Background: This Alert is intended to address the concerns of Federal, State, and local law enforcement agencies about occupational exposures of their officers to lead and noise during firearms training and qualifications. The Alert describes the health effects that can occur from occupational exposures to lead and noise at indoor firing ranges and recommends steps that firing range operators, employers, and workers should take to minimize the health risk to workers and shooters.

This guidance document does not have the force and effect of law.

Contact Person for Technical Information:

Chucri (Chuck) A. Kardous, Commander, U.S. Public Health Service, Senior Research Engineer, Division of Applied Research and Technology, CDC/NIOSH, 4676 Columbia Parkway, C27, Cincinnati, Ohio 45225, Phone: 513–533–8146, E-mail: *ckardous@cdc.gov.*

Reference: Web address for this document: *http://www.cdc.gov/niosh/review/public/128/.*

James D. Seligman,

Chief Information Officer, Centers for Disease Control and Prevention.

[FR Doc. E8–8259 Filed 4–16–08; 8:45 am]

BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Proposed Collection; Comment Request; Reinstatement of Generic Clearance for Partners and Customers Satisfaction Surveys

Summary: In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Center for Scientific Review (CSR), the National Institutes of Health (NIH) will publish periodic summaries of proposed projects. To request more information or to obtain a copy of the information collection plans, call the CSR Director of Planning, Analysis, and Evaluation on 301–435–1133.

Proposed Collection: Title: Reinstatement of Generic Clearance for Voluntary Partners and Customers